Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

CoPrimers™ used in proof of concept evaluation SALT LAKE CITY (BUSINESS WIRE) Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University. The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the The post Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University appeared first on Public Wire.
http://bit.ly/2Jbwu60